The business has seen sales in China collapse. And concern about the long-term effect that the corruption case will have on future revenue growth has weighed heavily on GlaxoSmithKline for many months now. So news last month that the case had been ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK) released the earnings results from its most recently completed quarter this morning, posting core earnings of 27.9 pence per share, excluding divestments.
There's no denying that Diageo (LSE: DGE) has underperformed this year. Concerns about the company's growth have spooked investors and sales within China have been hit hard by the government's anti-extravagance measures.
GlaxoSmithKline plc (ADR) (NYSE:GSK) reported Q3 earnings in which sales fell 10% but EPS exceeded estimates, and announced a cost savings plan, as revenues from its flagship respiratory drug Advair continued an extended decline.
Investors tend to turn to big blue-chip dividend payers at times of market volatility, and in times past the steady earnings of pharma giants GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) have been a particular source of comfort when the market ...
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has unfortunately gone one step too far on a number of occasions. The actions of its representatives in China have been put under the spotlight, and now more allegations are emerging from the Middle East.
[Bloomberg] GlaxoSmithKline plc (ADR) (NYSE:GSK) is exploring an initial public offering for its Viiv Healthcare Ltd. subsidiary to capitalize on the unit's soaring sales of HIV drugs even as revenue for the parent company declines.